<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17414" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Aluminum Hydroxide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shon</surname>
            <given-names>Nathaniel N.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yarbrough</surname>
            <given-names>Tracy</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nathaniel Shon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tracy Yarbrough declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17414.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Aluminum hydroxide is a medication used in the management and treatment of acid indigestion. It is in the antacid class of drugs. This activity outlines the indications, action, and contraindications for aluminum hydroxide as a valuable agent in the management of acid indigestion or topical burns. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the treatment of patients with acid reflux and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of aluminum hydroxide.</p></list-item><list-item><p>Describe the adverse effects and contraindications of aluminum hydroxide.</p></list-item><list-item><p>Review the toxicity of aluminum hydroxide.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to appropriately direct outcomes for patients receiving aluminum hydroxide.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17414&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17414">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17414.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Aluminum hydroxide is often administered orally for the temporary relief of heartburn or gastroesophageal reflux. It may be used topically, temporarily, to protect and relieve chafed and abraded skin, minor wounds and burns, and skin irritations resulting from friction and rubbing.<xref ref-type="bibr" rid="article-17414.r1">[1]</xref> Patients may also receive it to treat chemo-induced oral mucositis in the form of a mouthwash.<xref ref-type="bibr" rid="article-17414.r2">[2]</xref> Additionally, it is approved for use as an adjuvant in numerous vaccines due to its ability to increase phagocytosis and spur immune responses.<xref ref-type="bibr" rid="article-17414.r3">[3]</xref>&#x000a0;It also has approval for use in a wide array of cosmetic products at varying concentrations.<xref ref-type="bibr" rid="article-17414.r4">[4]</xref>&#x000a0;Aluminum hydroxide can also serve as a phosphate binder in patients with chronic renal disease. However, its use in this manner is infrequent due to the risk of adverse effects.<xref ref-type="bibr" rid="article-17414.r5">[5]</xref>&#x000a0;Commonly, oral aluminum hydroxide is a liquid formulation of both aluminum and magnesium hydroxide.&#x000a0;</p>
      </sec>
      <sec id="article-17414.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Aluminum hydroxide [Al(OH)3] dissociates into Al3+ and OH- in the stomach. The freed hydroxide groups then bind to free protons, ultimately producing water and insoluble aluminum salts, mostly Al(Cl)3, within the stomach. The proton binding serves to increase the overall pH of the stomach, i.e., less acidic, reducing the symptoms of indigestion. The produced aluminum salt primarily gets excreted in the feces, with less than 1% of the bioavailable aluminum absorbed within the GI tract.</p>
        <p>Aluminum exists at a steady-state within the body, so the body manages transient increases in aluminum uptake from use as an antacid with an equivalent increase in urinary excretion of unmodified aluminum. However, the setpoint of that steady-state may become elevated with prolonged increased intake of aluminum, so aluminum hydroxide treatment should not be considered as a long-term solution for patients suffering from acid indigestion. Furthermore, patients with chronic kidney disease may not be able to excrete the increased aluminum and thus also should be carefully considered.</p>
        <p>Topical aluminum hydroxide creates an acidic, hydrophilic layer over the area of irritation; this serves as a protective barrier to prevent infection and deter bacterial growth within the wound.&#x000a0;</p>
        <p>As an adjuvant in vaccines, aluminum hydroxide is known to increase macrophage phagocytosis, possibly via the upregulation of the NLRP3-inflammasome, increasing uptake of the desired antigen. Additionally, it is known to facilitate what is known as the "repository effect," whereby the antigens aggregate on and around the molecule, which helps to prevent their degradation within the body.<xref ref-type="bibr" rid="article-17414.r6">[6]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17414.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Aluminum hydroxide when used as an antacid is to be delivered orally. Shake the aluminum hydroxide suspension well before use. It should be taken 5 to 6 times daily after meals and at bedtime, not to exceed 3.84 g per 24 hours. The patient should follow the dose with water intake.</p>
        <p>Topical aluminum hydroxide should be applied to the desired area and left in place. Topical aluminum has minimal skin absorption, so topical treatment with aluminum hydroxide may require reapplication as necessary.&#x000a0;</p>
        <p>The administration of aluminum hydroxide as an antacid should not be for prolonged management of patient symptoms. Similarly, aluminum hydroxide should not be administered to patients with renal impairment. In these instances, increased aluminum may precipitate more severe adverse effects or deplete the body's phosphate reserves.<xref ref-type="bibr" rid="article-17414.r4">[4]</xref></p>
      </sec>
      <sec id="article-17414.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The primary side effects of aluminum hydroxide include hypomagnesemia, hypophosphatemia, constipation, and anemia.<xref ref-type="bibr" rid="article-17414.r5">[5]</xref>&#x000a0;Additionally, due to its ability to stimulate the immune system, there have been observed cases of persistent granulomas at the injection site of vaccines containing aluminum hydroxide.<xref ref-type="bibr" rid="article-17414.r7">[7]</xref>&#x000a0;Topical applications have not demonstrated any adverse effects, primarily because aluminum hydroxide does not get absorbed through the epidermis.<xref ref-type="bibr" rid="article-17414.r4">[4]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17414.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Aluminum hydroxide is contraindicated for patients with documented hypersensitivity to the drug. Prolonged administration should not be considered in a patient with renal impairment or a patient on dialysis, as impaired clearance of excess aluminum may precipitate the drug's adverse effects.<xref ref-type="bibr" rid="article-17414.r4">[4]</xref>&#x000a0;Due to aluminum hydroxide's ability to bind phosphate, it should not be administered in patients with severe diarrhea, as hypophosphatemia may become exacerbated. Additionally, the administration of aluminum hydroxide before the use of a fluoroquinolone such as ciprofloxacin has demonstrated a reduction in the bioavailability of the antimicrobial, reducing its efficacy. As such, it is not to be administered concurrently with these drugs. However, the patient can greatly mitigate this effect if the aluminum hydroxide is provided at least two hours after the antimicrobial.<xref ref-type="bibr" rid="article-17414.r8">[8]</xref><xref ref-type="bibr" rid="article-17414.r9">[9]</xref><xref ref-type="bibr" rid="article-17414.r10">[10]</xref>&#x000a0;Due to its nature as an alkalizing agent, it should also not be administered concurrently with drugs that depend upon acidic absorption, such as riociguat or raltegravir, as it will reduce the efficacy of these treatments.<xref ref-type="bibr" rid="article-17414.r11">[11]</xref><xref ref-type="bibr" rid="article-17414.r12">[12]</xref></p>
      </sec>
      <sec id="article-17414.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>When administering aluminum hydroxide as an antacid, the patient should have monitoring of their calcium and phosphate plasma concentrations. Kidney function also requires monitoring, especially with prolonged use of aluminum hydroxide.&#x000a0;</p>
      </sec>
      <sec id="article-17414.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Seizures, osteomalacia, and encephalopathy are well-documented toxic effects of aluminum hydroxide. Patients should be asked about any kidney issues before aluminum hydroxide administration, as these outcomes have strong correlations with aluminum hydroxide's use as a phosphate binder in patients on dialysis.<xref ref-type="bibr" rid="article-17414.r7">[7]</xref>&#x000a0;Most reports of encephalopathy and osteomalacia came from a period when water purification standards for dialysis were not as strong as they are now, likely confounding the relationship of oral aluminum to toxicity.&#x000a0;Reversal of aluminum hydroxide toxicity occurs with the cessation of the drug. Topical aluminum hydroxide and aluminum hydroxide adjuvant vaccines have not shown to produce any toxic effects, primarily due to the small concentration associated with both applications.&#x000a0;</p>
      </sec>
      <sec id="article-17414.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing the administration of aluminum hydroxide as an antacid to patients requires an interprofessional team of healthcare professionals that includes a nurse, laboratory technologists, pharmacists, social workers, and several physicians in different specialties. After the diagnosis of an illness treatable with aluminum hydroxide, such as heartburn, is made, care is necessary to ascertain if the patient possesses any risk factors or contraindications to aluminum hydroxide.&#x000a0;</p>
        <p>
<bold>Recommendations for Increasing Successful Outcomes of Antacid Aluminum Hydroxide Therapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Discontinue administration of aluminum hydroxide in patients with renal impairment.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Do not administer aluminum hydroxide concurrently with antimicrobials such as fluoroquinolones.</p>
          </list-item>
          <list-item>
            <p>Avoid the use of antacid treatment in patients taking medications that depend upon the acidic nature of the stomach for proper absorption.</p>
          </list-item>
          <list-item>
            <p>Prescribe aluminum hydroxide for temporary use rather than prolonged management</p>
          </list-item>
          <list-item>
            <p>Discontinue administration of aluminum hydroxide when used as an antacid if the patient develops severe diarrhea</p>
          </list-item>
        </list>
        <p>The clinician and nurses should monitor the patient and report untoward findings to the team. Pharmacists can also counsel the patient regarding dosing and the proper application of topical dose forms. The pharmacist should also check for drug interactions. Complications or issues with therapy should be reported to the medical team. All practitioners should be aware of the potential problems of long-term use, and counsel and direct the patient accordingly, particularly in those with renal compromise. Interprofessional monitoring of patients taking aluminum hydroxide will lead to better outcomes. [Level 5]</p>
      </sec>
      <sec id="article-17414.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17414&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17414">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17414/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17414">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17414.s11">
        <title>References</title>
        <ref id="article-17414.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Margolis</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>VL</given-names>
              </name>
            </person-group>
            <article-title>A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers.</article-title>
            <source>Dermatol Surg</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-8</page-range>
            <pub-id pub-id-type="pmid">7894932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ignoffo</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Survey of topical oral solutions for the treatment of chemo-induced oral mucositis.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>139</fpage>
            <page-range>139-43</page-range>
            <pub-id pub-id-type="pmid">16595065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Advances in aluminum hydroxide-based adjuvant research and its mechanism.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2015</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>477</fpage>
            <page-range>477-88</page-range>
            <pub-id pub-id-type="pmid">25692535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bergfeld</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Belsito</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Klaassen</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Liebler</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Shank</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Slaga</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Safety Assessment of Alumina and Aluminum Hydroxide as Used in Cosmetics.</article-title>
            <source>Int J Toxicol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>3 suppl</issue>
            <fpage>16S</fpage>
            <page-range>16S-33S</page-range>
            <pub-id pub-id-type="pmid">27913785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willhite</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Karyakina</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Yokel</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Yenugadhati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wisniewski</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Momoli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Krewski</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.</article-title>
            <source>Crit Rev Toxicol</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>44 Suppl 4</volume>
            <issue>Suppl 4</issue>
            <fpage>1</fpage>
            <page-range>1-80</page-range>
            <pub-id pub-id-type="pmid">25233067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hogenesch</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of immunopotentiation and safety of aluminum adjuvants.</article-title>
            <source>Front Immunol</source>
            <year>2012</year>
            <volume>3</volume>
            <fpage>406</fpage>
            <pub-id pub-id-type="pmid">23335921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krewski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yokel</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Nieboer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Borchelt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kacew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mahfouz</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rondeau</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.</article-title>
            <source>J Toxicol Environ Health B Crit Rev</source>
            <year>2007</year>
            <volume>10 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>1</fpage>
            <page-range>1-269</page-range>
            <pub-id pub-id-type="pmid">18085482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golper</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Hartstein</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Morthland</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>1787</fpage>
            <page-range>1787-90</page-range>
            <pub-id pub-id-type="pmid">3435126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frost</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Lasseter</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Noe</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Shamblen</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Lettieri</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1992</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>830</fpage>
            <page-range>830-2</page-range>
            <pub-id pub-id-type="pmid">1503446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arayne</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sultana</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Interactions between ciprofloxacin and antacids--dissolution and adsorption studies.</article-title>
            <source>Drug Metabol Drug Interact</source>
            <year>2005</year>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-29</page-range>
            <pub-id pub-id-type="pmid">16355977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krishna</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>East</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Valiathan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Butterfield</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hernandez-Illas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.</article-title>
            <source>J Pharm Pharmacol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>11</issue>
            <fpage>1359</fpage>
            <page-range>1359-1365</page-range>
            <pub-id pub-id-type="pmid">27671833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17414.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Artmeier-Brandt</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Weimann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ck</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption.</article-title>
            <source>Pulm Circ</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>Suppl 1</issue>
            <fpage>S43</fpage>
            <page-range>S43-8</page-range>
            <pub-id pub-id-type="pmid">27162626</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
